Thomasville National Bank’s ImmunityBio IBRX Stock Holding History

Thomasville National Bank’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$131K	Buy	+15,000	New	+$114K	0.01%	238

Other funds holding IBRX

Pictet Asset Management

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Kercheville Advisors San Antonio, Texas $328M AUM 76.85% 1-Year Est. Return

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

Sheets Smith Wealth Management Winston-Salem, North Carolina $1B AUM 29.77% 1-Year Est. Return

Legacy Capital Group California Los Gatos, California $332M AUM 42.15% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Plancorp LLC Saint Louis, Missouri $4.1B AUM 25.19% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

MFG Wealth Management Indianapolis, Indiana $140M AUM 44.72% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Thomasville National Bank's IBRX Position: Q2 2026 in Review

Thomasville National Bank opened a new position in ImmunityBio (IBRX) in Q2 2026: 15,000 shares worth $131K. The stake represents 0.01% of the portfolio and ranks #238 among its holdings.

133 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Thomasville National Bank held 15,000 shares of ImmunityBio worth $131K as of Q2 2026.
ImmunityBio was a new Thomasville National Bank position in Q2 2026.
ImmunityBio made up 0.01% of Thomasville National Bank's portfolio in Q2 2026, its #238 holding.
133 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Thomasville National Bank's 13F filing for Q2 2026, filed 20 Jul 2026.